L
Liverpool Chirochem
Specialist in chiral molecules for pharmaceutical research
About Liverpool Chirochem
Liverpool ChiroChem (LCC) is a chemical technology company that specializes in producing chiral small molecules for the pharmaceutical and biotechnology research and development sectors. The company's products serve as building blocks, fragments, and screening compounds for drug discovery.
LCC was founded in 2014 as a spin-out from the University of Liverpool's Department of Chemistry. The founders include Professor Jianliang Xiao and his two former PhD students, Dr. Jianjun Wu and Dr. Paul Colbon, who now serves as the company's CEO, along with Dr. Jiwu Ruan, a postdoctoral researcher from Xiao's group. Paul Colbon graduated from the University of Liverpool with an MChem and a PhD, and previously worked at AstraZeneca and Redx Pharma. The company was established based on patented catalytic methods developed at the university that allow for simpler, lower-cost production of chiral compounds.
The company's primary clients are multinational pharmaceutical companies, contract research organizations (CROs), and specialist biotech firms across the United States, Europe, and Asia. Revenue is generated through the sale of its proprietary chemical compounds and custom synthesis services. A key technology is its Parallel Automated Chiral Engine (PACE), which integrates AI software and automation to design and synthesize novel chiral molecules. This platform has produced a vast collection of chiral building blocks and a proprietary virtual library of over one billion compounds.
In June 2025, following a period of administration for its entity LCC Therapeutics, Liverpool ChiroChem was acquired by XtalPi, a life sciences R&D platform that utilizes quantum physics, AI, and robotics. The acquisition, described as a strategic merger, is intended to enhance XtalPi's capabilities in exploring and synthesizing new chemical spaces for various applications, including pharmaceuticals, materials, and agriculture. Dr. Paul Colbon has remained as CEO to guide the collaboration between the two teams.
Source: Dealroom company dataNews
Open roles
Liverpool Chirochem in the Liverpool ecosystem
The Liverpool Chirochem office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Praetura Ventures
Northern Powerhouse Investment Fund
Deepbridge Capital
Series B and later6 investors entered at this stage
Maven Capital Partners
Future Fund
Cheshire and Warrington Local Enterprise Partnership
Greater Manchester Combined Authority
Bruntwood
Gmctrading
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Liverpool Chirochem on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Liverpool Chirochem on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

